Brief: Century Therapeutics Presents Initial Data From Cnty-101 Phase 1 Elipse-1 Trial Supporting The Potential For A Multi-Dosing Strategy For Car Ink Enabled By Allo-Evasion Edits

Century Therapeutics

09/12/2023 23:57

Dec 9 (Reuters) - Century Therapeutics Inc  IPSC.O :
    * CENTURY THERAPEUTICS PRESENTS INITIAL DATA FROM CNTY-101
PHASE 1
ELIPSE-1 TRIAL SUPPORTING THE POTENTIAL FOR A MULTI-DOSING
STRATEGY FOR CAR INK ENABLED BY ALLO-EVASION™ EDITS
    * CENTURY THERAPEUTICS - DATA SHOW CNTY-101 WAS GENERALLY
WELL
TOLERATED AT DOSE LEVEL 1 (100 MILLION CELLS) IN A HIGH-RISK,
HEAVILY PRETREATED R/R B-CELL LYMPHOMA PATIENT

Source text for Eikon:  ID:nGNX6rHVx7 
Further company coverage:  IPSC.O 

 ((Reuters.Briefs@thomsonreuters.com;))